Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Research Article

Design, Synthesis, Docking and Computational Pharmacokinetic Profiling of New Pyrazolinyl Thiazolinone Biheterocycles as Potent Antimicrobial Agents

Author(s): Vinutha Vittala Salian, Badiadka Narayana*, Balladka Kunhanna Sarojini, Sharath Chandra Kodandoor and Anupam Glorious Lobo

Volume 17, Issue 11, 2020

Page: [1342 - 1354] Pages: 13

DOI: 10.2174/1570180817999200623115049

Price: $65

Abstract

Background: Development of potential antimicrobial agents is the main aim in the drug discovery process to overcome the problem of drug resistance. Pyrazolines and thiazolinones are extensively used as building blocks for the synthesis of diverse and medicinally important compounds.

Methods: In this present work, a new series of functionalized pyrazolinyl-thiazolinone biheterocycles is designed and synthesized from N-pyrazolinecarbothioamide. Antimicrobial screening is carried out in order to discover their potential towards six bacterial and four fungal strains. The zone of inhibition (ZI in mm) was determined by the disc diffusion method and minimum inhibitory concentration (MIC in μg/mL) by macro dilution method. The druggability of these new entities is done through in silico pharmacokinetic profiling using Maestro 2017-1 interface of Schrӧdinger software.

Results and Disscusion: Compounds 4c and 4e with chloro and iodo substituents on Nphenylacetamide ring displayed good inhibitory antibacterial activity against the tested bacterial strains with minimum MIC values when compared to the reference drug tetracycline. Compound 3 with an acetic acid derivative showed high antifungal activity among all the tested derivatives. Compound 3 not only showed antifungal activity but also qualified druggability test with no violation of Lipinski rule of five.

Conclusion: The capability of the synthesized pyrazolinyl-thiazolinone derivatives was performed to efficiently inhibit the growth of microorganisms against selected bacterial and fungal strains. Further, these compounds are found to be effectively bound to the active sites of attractive target Escherichia coli FabH.

Keywords: Pyrazoline, thiazolinone, antimicrobial, molecular docking, pharmacokinetics, Lipinski rule of five.

« Previous Next »
Graphical Abstract

[1]
Matsushita M, Janda KD. Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem 2002; 10(4): 855-67.
[http://dx.doi.org/10.1016/S0968-0896(01)00355-8] [PMID: 11836091]
[2]
Li X, Ma S. Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ. Eur J Med Chem 2015; 95: 1-15.
[http://dx.doi.org/10.1016/j.ejmech.2015.03.026] [PMID: 25791674]
[3]
Jose G. Kumara, T.H.S.; Nagendrappa, G.; Sowmya, H.B.V.; Jasinski, J.P.; Millikan, S.P.; Chandrika, N.; More, S.S.; Harish, B.G. New polyfunctional imidazo[4,5-c]pyridine motifs: syntheis, crystal studies, docking studies and antimicrobial evaluation. Eur J Med Chem 2014; 77: 288-97.
[http://dx.doi.org/10.1016/j.ejmech.2014.03.019] [PMID: 24657565]
[4]
Wright HT, Reynolds KA. Antibacterial targets in fatty acid biosynthesis. Curr Opin Microbiol 2007; 10(5): 447-53.
[http://dx.doi.org/10.1016/j.mib.2007.07.001] [PMID: 17707686]
[5]
Cronan JE, Thomas J. Bacterial fatty acid synthesis and its relationships with polyketide synthetic pathways. Methods Enzymol 2009; 459: 395-433.
[http://dx.doi.org/10.1016/S0076-6879(09)04617-5] [PMID: 19362649]
[6]
Zhang YM, White SW, Rock CO. Inhibiting bacterial fatty acid synthesis. J Biol Chem 2006; 281(26): 17541-4.
[http://dx.doi.org/10.1074/jbc.R600004200] [PMID: 16648134]
[7]
Sarojini BK, Krishna BG, Darshanraj CG, Bharath BR, Manjunatha H. Synthesis, characterization, in vitro and molecular docking studies of new 2,5-dichloro thienyl substituted thiazole derivatives for antimicrobial properties. Eur J Med Chem 2010; 45(8): 3490-6.
[http://dx.doi.org/10.1016/j.ejmech.2010.03.039] [PMID: 20451305]
[8]
Narayana B, Vijaya Raj KK, Ashalatha BV, Kumari NS, Sarojini BK. Synthesis of some new 5-(2-substituted-1,3-thiazol-5-yl)-2-hydroxy benzamides and their 2-alkoxy derivatives as possible antifungal agents. Eur J Med Chem 2004; 39(10): 867-72.
[http://dx.doi.org/10.1016/j.ejmech.2004.06.003] [PMID: 15464620]
[9]
Holla BS, Malini KV, Rao BS, Sarojini BK, Kumari NS. Synthesis of some new 2,4-disubstituted thiazoles as possible antibacterial and anti-inflammatory agents. Eur J Med Chem 2003; 38(3): 313-8.
[http://dx.doi.org/10.1016/S0223-5234(02)01447-2] [PMID: 12667698]
[10]
Li JR, Li DD, Wang RR, et al. Design and synthesis of thiazole derivatives as potent FabH inhibitors with antibacterial activity. Eur J Med Chem 2014; 75: 438-47.
[http://dx.doi.org/10.1016/j.ejmech.2013.11.020] [PMID: 24561667]
[11]
Andres CJ, Bronson JJ, D’Andrea SV, et al. 4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB. Bioorg Med Chem Lett 2000; 10(8): 715-7.
[http://dx.doi.org/10.1016/S0960-894X(00)00073-1] [PMID: 10782671]
[12]
Salian VV, Narayana B, Sarojini BK, Byrappa K. A comprehensive review on recent developments in the field of biological applications of potent pyrazolines derived from chalcone precursors. Lett Drug Des Discov 2018; 15: 516-74.
[http://dx.doi.org/10.2174/1570180814666170703164221]
[13]
Vardar-Unlu G, Candan F, Sokemen F, Daferra D, Pollissiou M, Sokemen M. Antimicrobial and antioxidant activity of the essential Oil and methanol extract of Thymus pectinatus. J Agric Food Chem 2003; 51: 63-7.
[http://dx.doi.org/10.1021/jf025753e] [PMID: 12502386]
[14]
Akinyemi KO, Oladapo O, Okwara CE, Ibe CC, Fasure KA. Screening of crude extracts of six medicinal plants used in South-West Nigerian unorthodox medicine for anti-methicillin resistant Staphylococcus aureus activity. BMC Complement Altern Med 2005; 5: 6.
[http://dx.doi.org/10.1186/1472-6882-5-6] [PMID: 15762997]
[15]
Salian VV, Narayana B, Sarojini BK, Kumar MS, Sharath Chandra K, Lobo AG. Tailor made biheterocyclic pyrazoline-thiazolidinones as effective inhibitors of Escherichia coli FabH: design, synthesis and structural studies. J Mol Struct 2019; 1192: 91-104.
[http://dx.doi.org/10.1016/j.molstruc.2019.04.105]
[16]
Salian VV, Narayana B, Sarojini BK, Sindhupriya ES, Madhu LN, Rao S. Biologically potent pyrazoline derivatives from versatile (2)-1-(4-chlorophenyl)-3-[4-(propan-2-yl)phenyl]prop-2-en-1-one. Lett Drug Des Discov 2017; 14: 216-27.
[http://dx.doi.org/10.2174/1570180813666160519151723]
[17]
Salian VV, Narayana B, Sarojini BK, et al. Spectroscopic, single crystal X-ray, Hirshfeld, in vitro and in silico biological evaluation of a new series of potent thiazole nucleus integrated with pyrazoline scaffolds. Spectrochim Acta A Mol Biomol Spectrosc 2017; 174: 254-71.
[http://dx.doi.org/10.1016/j.saa.2016.11.046] [PMID: 27936436]
[18]
Narayana B, Salian VV, Sarojini BK, Jasinski JP. (2E)-1-(4-Chloro-phen-yl)-3-[4-(propan-2-yl)phen-yl]prop-2-en-1-one. Acta Crystallogr Sect E Struct Rep Online 2014; 70(Pt 8): o855.
[http://dx.doi.org/10.1107/S1600536814015281] [PMID: 25249906]
[19]
Salian VV, Narayana B, Sarojini BKN. -(4-Nitrophenyl)-2-2-[3-(4-chlorophenyl)-5-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5-ylacetamide. Molbank 2017; 2017: M943.
[http://dx.doi.org/10.3390/M943]
[20]
Selvaggi G, Monstrey S, Van Landuyt K, Hamdi M, Blondeel P. The role of iodine in antisepsis and wound management: a reappraisal. Acta Chir Belg 2003; 103(3): 241-7.
[http://dx.doi.org/10.1080/00015458.2003.11679417] [PMID: 12914356]
[21]
Brooks WH, Guida WC, Daniel KG. The significance of chirality in drug design and development. Curr Top Med Chem 2011; 11(7): 760-70.
[http://dx.doi.org/10.2174/156802611795165098] [PMID: 21291399]
[22]
QikProp, version 44 Schrödinger, LLC New York, NY. 2015.
[23]
Bohnert T, Prakash C. ADME profiling in drug discovery and development: an overview Part III General principles of ADME Drug transporters and other mechanisms of transport Encyclopedia of drug metabolisms and interactions
[24]
van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 2005; 1(2): 175-85.
[http://dx.doi.org/10.1517/17425255.1.2.175] [PMID: 16922635]
[25]
Jing Y, Easter A, Peters D, Kim N, Enyedy IJ. In silico prediction of hERG inhibition. Future Med Chem 2015; 7(5): 571-86.
[http://dx.doi.org/10.4155/fmc.15.18] [PMID: 25921399]

Rights & Permissions Print Cite
Article Metrics
8
© 2024 Bentham Science Publishers | Privacy Policy